



## 2021 ILTS-SETH CONSENSUS CONFERENCE

Non-hepatic Cancer and Liver Transplantation: Shifting the Paradigm. Dropping the Cancer Stigma.

### INTRODUCTION

A significant and growing number of patients in need of liver transplantation (LT) have a history of cancer. Management of these patients is challenging, as history of a pre-transplant malignancy (PTM) in remission has long been considered a relative contraindication due to the concern that immunosuppression required to prevent graft rejection would allow the growth of dormant malignant cells in these patients. Recommendations for listing transplant candidates with PTM were based primarily on the recurrence rates in kidney transplant recipients derived from the Israel Penn International Transplant Tumour Registry (IPITTR, previously known as the Cincinnati Transplant Tumour Registry), a voluntary database of transplant recipients with malignancies. Data from the IPITTR indicated that the recurrence rate of PTM was 21% or a rate of 5.6 cancer recurrences per 100 person/year of follow-up, and that most recurrences (53%) occurred in those transplanted within two years of a cancer diagnosis or treatment. However, these studies were done decades ago, and several more recent population-based cohort studies and systemic reviews with meta-analyses have reported markedly lower rates of recurrence in recipients with PTM.

Currently, guidelines for the selection of liver transplant candidates generally recommend minimum wait-times before


transplantation for patients with PTM that range from no wait-time for some in situ malignancies to more than five years for melanoma, bladder, colorectal, and breast cancer, provided that the neoplasms have been eradicated and that the oncologic expected survival is superior to the survival expected after LT. Unfortunately, most of the guidelines are based on data from the kidney transplantation arena and do not take substantial recent improvements in cancer therapy (including immunotherapy) into consideration.

In addition, as older donors are increasingly utilized, the risk of non-liver cancer in some of these donors, either in the past medical history or found incidentally after donation has also increased, and it must be established how to manage recipients transplanted with these organs.

Finally, de novo cancer is one of the most frequent causes of death in liver transplant recipients with studies showing an association between cumulated immunosuppression and risk of cancer.

In essence, the increasing number of liver transplant candidates with a history of cancer, and that of recipients who develop cancer post-transplantation, together with the improvement in oncology therapy, calls for a more thorough evaluation of the risk of post-transplant cancer development as well as management of these patients.


#### ILTS President

  
Claus Niemann, MD  
UCSF, San Francisco, USA


#### ILTS President-Elect 2020-21


  
Marina Berenguer, MD  
La Fe University  
Hospital, Valencia,  
Spain

#### ILTS President-Elect 2021-22

  
Mohamed Rela, MS,  
FRCS, DSc  
Dr. Rela Institute  
and Medical Center,  
Chennai, India

#### ILTS-SETH 2021 Consensus Conference Topic Coordinators:

  
Kymberly Watt, MD  
Mayo Clinic, Rochester, USA

  
Jordi Colmenero, MD, PhD  
Hospital Clinic Barcelona,  
Barcelona, Spain

#### SETH President

  
José Antonio Pons,  
MD, PhD  
Virgen de la Arrixaca  
University Hospital,  
Murcia, Spain

## 2021 ILTS-SETH CONSENSUS CONFERENCE

Non-hepatic Cancer and Liver Transplantation: Shifting the Paradigm. Dropping the Cancer Stigma.

In this Consensus Conference, we will discuss:

- How to evaluate the presence of malignancies in liver transplant candidates;
- The risk and post-LT surveillance for those with a history of pre-transplant malignancy in remission;
- Who is safe to donate a liver with a history of cancer (deceased or live donor/cancer detected during donor work-up) and what could be done if the recipient develops a malignancy transmitted from a donor;
- Factors that increase the risk of post-transplant non-hepatic malignancies and how to manage immunosuppression and onco-specific therapies in these patients;
- Whether surveillance is cost-beneficial in high-risk individuals;
- Whether the data applies to pediatrics.

### LEARNING OBJECTIVES

1. Understand the gap between current practice and future transplant-related oncology.
2. Update selection criteria and prediction models in candidates with a history of prior malignancy in remission.
3. Identify when it is safe to donate a liver from a candidate with a history of cancer or with cancer detected during the transplant work-up.
4. Identify novel biological, chemotherapeutic, radiological, and immunotherapeutic approaches for patients with de novo cancer developing after liver transplantation.

### EXPECTED EDUCATIONAL OUTCOMES

The participants will be able to review and discuss research regarding non-hepatic malignancy in the candidate, the donor or the recipient, including selection criteria/indications, prognostic models, surveillance strategies, novel therapies and management. The participants will gain insight into innovations that lead to improvement in the field of liver transplantation in candidates or donors with a history of malignancy, and in recipients with de novo cancer, both in adult and pediatric populations.

### TARGET AUDIENCE

- Surgeons
- Hepatologists
- Pathologists
- Radiologists
- Oncologists
- Scientists
- Nurses

## 2021 ILTS-SETH CONSENSUS CONFERENCE

Non-hepatic Cancer and Liver Transplantation: Shifting the Paradigm. Dropping the Cancer Stigma.

### Scientific Program | Thursday, January 28, 2021

#### 13:00 - 18:10 **Consensus Conference Lectures**

(Open to all participants)

**13:00 - 13:10**

##### **Introduction**

José Antonio Pons, MD, PhD *Virgen de la Arrixaca University Hospital, Murcia, Spain*

**13:10 - 14:40**

##### **General Concepts**

**Chairs:**

Marina Berenguer, MD *La Fe University Hospital, Valencia, Spain*

José Antonio Pons, MD, PhD *Virgen de la Arrixaca University Hospital, Murcia, Spain*

13:10 - 13:25

Liver transplantation outcomes and current candidates profile  
Nazia Selzner, MD, PhD *University of Toronto, Toronto, Canada*

13:25 - 13:40

Outlining the current approach to non-hepatic cancer in LT  
John Roberts, MD *UCSF, San Francisco, USA*

13:40 - 13:55

Role of immunosuppression in cancer  
Manuel Rodríguez-Perálvarez, MD, PhD *Reina Sofia University Hospital, Cordoba, Spain*

13:55 - 14:10

New anti-cancer therapies: Beyond the conventional multidisciplinary cancer care  
Milind Javle, MD *University of Texas MD Anderson Cancer Center, Houston, USA*

14:10 - 14:40

Q&A

14:40 - 14:55

Break

**14:55 - 16:10**

##### **Pre-transplant Considerations: Work-up for Recipient and Donor Candidates**

**Chairs:**

Itxarone Bilbao, MD *Vall d'Hebron University Hospital, Barcelona, Spain*

Mohamed Rela, MS, FRCS, DSc *Dr. Rela Institute and Medical Center, Chennai, India*

14:55 - 15:10

How to manage LT candidates with a history of cancer/newly diagnosed cancer during pre-transplant work-up?  
Sergio A. Acuna, MD, PhD *University of Toronto, Toronto, Canada*

15:10 - 15:25

How to proceed with deceased donors with a history of cancer/cancer-like lesions found at the time of procurement?  
Beatriz Domínguez-Gil, MD, PhD *National Transplant Organization, Madrid, Spain*

15:25 - 15:40

How to proceed with living donors with a history of cancer or precancerous lesions/early-stage cancer found at the time of evaluation?  
Dong-Hwan Jung, MD, PhD *Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea*

15:40 - 16:10

Q&A

16:10 - 16:25

Break

## 2021 ILTS-SETH CONSENSUS CONFERENCE

Non-hepatic Cancer and Liver Transplantation: Shifting the Paradigm. Dropping the Cancer Stigma.

- 16:25 - 17:55**      **Post-transplant Considerations: De Novo Malignancies in LT Recipients**  
Chairs:  
Gonzalo Crespo, MD *Hospital Clinic de Barcelona, Barcelona, Spain*  
Mark Ghobrial, MD, PhD, FRCS *Houston Methodist Hospital, Houston, USA*
- 16:25 - 16:40      Incidence and risk factors  
Kymberly Watt, MD *Mayo Clinic, Rochester, USA*
- 16:40 - 16:55      Screening strategies after liver transplantation  
José Ignacio Herrero, MD *University Clinic of Navarra, Pamplona, Spain*
- 16:55 - 17:10      Treatment for solid tumors  
Gonzalo Sapisochin, MD *UHN - Toronto General Hospital, Toronto, Canada*
- 17:10 - 17:25      Treatment for post-transplant lymphoproliferative disorders (PTLD)  
Dok Hyun Yoon, MD *Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea*
- 17:25 - 17:55      Q&A
- 17:55 - 18:10**      **Presidential address**  
Claus Niemann, MD *UCSF, San Francisco, USA*

## 2021 ILTS-SETH CONSENSUS CONFERENCE

Non-hepatic Cancer and Liver Transplantation: Shifting the Paradigm. Dropping the Cancer Stigma.

### Scientific Program | Friday, January 29, 2021

---

#### 13:00 - 16:30 Afternoon Working Groups

(Working Group participation is limited to 30 pre-registered participants per group. Final selection will be made by the Topic Coordinators)

13:00 - 13:15

##### Introduction

###### Topic coordinators:

Jordi Colmenero, MD, PhD *Hospital Clinic Barcelona, Barcelona, Spain*

Kymerly Watt, MD *Mayo Clinic, Rochester, USA*

#### Working Group 1: Non-hepatic Cancer in LT Candidates

###### Working Group Coordinators:

Magdalena Salcedo, MD, PhD *Gregorio Marañón General University Hospital, Madrid, Spain*

Pål-Dag Line, MD, PhD *Rikshospitalet, Oslo, Norway*

###### Working Group Members:

Milind Javle, MD *University of Texas MD Anderson Cancer Center, Houston, USA*

María Trapero, MD, PhD *Autonomous University of Madrid, Madrid, Spain*

Francisco Javier Bustamante, MD *Cruces University Hospital, Bilbao, Spain*

Carmen Vinaixa, MD *La Fe University Hospital, Valencia, Spain*

Paolo de Simone, MD *University of Pisa Medical School Hospital, Pisa, Italy*

- 1.1. Evaluation of candidates. Timing to transplantation (tumor staging, treatments..)
- 1.2. Immunotherapy before the transplant: Specific measures at transplantation
- 1.3. Management after liver transplantation (immunosuppression, lifestyle and habits)
- 1.4. Specific considerations for each type of cancer

#### Working Group 2: De novo Malignancies after LT

###### Working Group Coordinators:

Jordi Colmenero, MD, PhD *Hospital Clinic Barcelona, Barcelona, Spain*

Kymerly Watt, MD *Mayo Clinic, Rochester, USA*

###### Working Group Members:

Manuel Rodriguez-Perálvarez, MD, PhD *Reina Sofia University Hospital, Cordoba, Spain*

José Ignacio Herrero, MD *University Clinic of Navarra, Pamplona, Spain*

Sherrie Bhoori, MD *National Cancer Institute of Milan, Milan, Italy*

Marco Senzolo, MD *University Hospital of Padua, Padua, Italy*

Prashant Bhangui, MBBS, MS *Institute of Liver Transplantation and Regenerative Medicine, Medanta, Gurgaon, India*

- 2.1. Epidemiology, risk factors and survival
- 2.2. Preventive strategies, surveillance of extrahepatic cancers
- 2.3. Management of immunosuppression in patients with de novo cancer

## 2021 ILTS-SETH CONSENSUS CONFERENCE

Non-hepatic Cancer and Liver Transplantation: Shifting the Paradigm. Dropping the Cancer Stigma.

### Working Group 3: Prevention and Management of Donor-derived Malignancies after LT (Deceased and Living Donors)

#### Working Group Coordinators:

Beatriz Domínguez-Gil, MD, PhD *National Transplant Organization, Madrid, Spain*

François Durand, MD, PhD *University Paris VII, Paris, France*

#### Working Group Members:

María Trinidad Serrano, MD, PhD *Lozano Blesa University Hospital Clinic, Zaragoza, Spain*

José Manuel Asencio, MD, PhD, FACS *Gregorio Marañón General University Hospital, Madrid, Spain*

Marieke Van Rosmalen, MD *Eurotransplant International Foundation, Leiden, The Netherlands*

Julie Heimbach, MD *Mayo Clinic, Rochester, USA*

Taizo Hibi, MD, PhD, FACS *Kumamoto University Graduate School of Medical Sciences, Kumamoto, Japan*

Olivier Detry, MD, PhD *University of Liège, Liège, Belgium*

Kerstin Mönch, MD *Westpfalz-Hospital, Kaiserslautern, Germany*

Christopher Watson, MD, PhD *University of Cambridge, Cambridge, United Kingdom*

- 3.1. Epidemiology and risk factors - surveillance
- 3.2. How to minimize the occurrence of donor transmitted malignancies in liver transplant recipients
- 3.3. Specificities of the live liver donor with regards to donor transmitted malignancies
- 3.4. Assessment of risk and management based on individual tumor types
- 3.5. How to proceed in case of a suspected malignancy transmission (including early re-transplantation)

### Working Group 4: Non-hepatic Cancer in the Pediatric Population

#### Working Group Coordinators:

Itxarone Bilbao, MD *Vall d'Hebron University Hospital, Barcelona, Spain*

Mohamed Rela, MS, FRCS, DSc *Dr. Rela Institute and Medical Center, Chennai, India*

#### Working Group Members:

Francisco Hernández-Oliveros, MD, PhD *University Hospital La Paz, Madrid, Spain*

Jesús Quintero, MD *Vall d'Hebron University Hospital, Barcelona, Spain*

Paolo Muiesan, MD *Elizabeth Hospital Birmingham, Birmingham, UK*

Mureo Kasahara, MD *National Center for Child Health and Development, Tokyo, Japan*

- 4.1. Extrahepatic solid tumors before pediatric LT
- 4.2. Leukemia, lymphoma and other hematologic disturbances before pediatric LT
- 4.3. Malignancies following pediatric LT, different approaches to post-transplant lymphoproliferative disorder

### Working Group 5: Onco-specific Therapies after LT

#### Working Group Coordinators:

Mikel Gastaca, MD *Cruces University Hospital, Bilbao, Spain*

Parissa Tabrizian, MD, MSc *Icahn School of Medicine at Mount Sinai, New York, USA*

#### Working Group Members:

Gonzalo Sapisochin, MD *UHN - Toronto General Hospital, Toronto, Canada*

Sonia Pascual, MD *HGU Alicante, Alicante, Spain*

David James Pinato, MD, PhD *Imperial College London, London, UK*

David Al-Adra, MD, PhD *University of Wisconsin School of Medicine and Public Health, Madison, USA*

Henrik Petrowsky, MD, FACS *University Hospital Zurich, Zurich, Switzerland*

- 5.1. Surgical management
- 5.2. Oncological medical therapy including immunotherapy post LT
- 5.3. Radiological therapies post LT

## 2021 ILTS-SETH CONSENSUS CONFERENCE

Non-hepatic Cancer and Liver Transplantation: Shifting the Paradigm. Dropping the Cancer Stigma.

### Scientific Program | Saturday, January 30, 2021

---

#### **13:00 - 16:00 Working Group Presentations**

(Open to all participants)

#### **13:00 - 14:30 Working Group Presentations with Summarizing Statements**

13:00 - 13:30 Working Group 1 - Summarizing Statements and Q&A

13:30 - 14:00 Working Group 2 - Summarizing Statements and Q&A

14:00 - 14:30 Working Group 3 - Summarizing Statements and Q&A

14:30 - 14:45 Break

#### **14:45 - 15:45 Working Group Presentations with Summarizing Statements**

14:45 - 15:15 Working Group 4 - Summarizing Statements and Q&A

15:15 - 15:45 Working Group 5 - Summarizing Statements and Q&A

#### **15:45 - 16:00 Consensus Conclusion**

## 2021 ILTS-SETH CONSENSUS CONFERENCE

Non-hepatic Cancer and Liver Transplantation: Shifting the Paradigm. Dropping the Cancer Stigma.

**The International Liver Transplantation Society (ILTS) and Spanish Liver Transplantation Society (SETH) jointly prepared this Consensus Conference:**

### Topic Coordinators:

- **Jordi Colmenero, MD, PhD** *Hospital Clinic Barcelona, Barcelona, Spain (SETH)*
- **Kymberly Watt, MD** *Mayo Clinic, Rochester, USA (ILTS)*

### Steering Committee Members:

- **José Antonio Pons, MD, PhD** *Virgen de la Arrixaca University Hospital, Murcia, Spain (SETH)*
- **Magdalena Salcedo, MD, PhD** *Gregorio Marañón General University Hospital, Madrid, Spain (SETH)*
- **Itxarone Bilbao, MD** *Vall d'Hebron University Hospital, Barcelona, Spain (SETH)*
- **Mikel Gastaca, MD** *Cruces University Hospital, Bilbao, Spain (SETH)*
- **Prashant Bhangui, MBBS, MS** *Institute of Liver Transplantation and Regenerative Medicine, Medanta, Gurgaon, India (ILTS)*
- **Eleonora de Martin, MD** *Hospital Paul Brousse, Villejuif, France (ILTS)*
- **Roberto Hernandez-Alejandro, MD, FACS, FRCSC** *University of Rochester Medical Center, Rochester, USA (ILTS)*
- **Mina Komuta, MD** *Keio University, Tokyo, Japan (ILTS)*

### ILTS President 2019 – 2020:

- **Claus Niemann, MD** *UCSF, San Francisco, USA*

### ILTS President-Elect 2020 – 2021:

- **Marina Berenguer, MD** *La Fe University Hospital, Valencia, Spain*

### ILTS President-Elect 2021 – 2022:

- **Mohamed Rela, MS, FRCS, DSc** *Dr. Rela Institute and Medical Center, Chennai, India*



## 2021 ILTS-SETH CONSENSUS CONFERENCE

Non-hepatic Cancer and Liver Transplantation: Shifting the Paradigm. Dropping the Cancer Stigma.

### TIME AND DATE

#### Consensus Conference Lectures

January 28, 2021

13:00 - 18:10

#### Working Groups

January 29, 2021

13:00 - 16:30

#### Working Group Presentations with Summarizing Statements / Consensus Conclusions

January 30, 2021

13:00 - 16:00

#### Time Zone

CET (Central European Time)

Check corresponding international time zones [here](#).

### REGISTRATION

Please register [here](#) by January 28, 2021.

Should you require further assistance, please don't hesitate to contact the ILTS Registration Department:

E-mail: [registration-consensus@ilts.org](mailto:registration-consensus@ilts.org)

Hotline: +49 (0) 30 24603 410

### ILTS HEADQUARTERS

K.I.T. Group GmbH  
Association & Conference Management  
Kurfürstendamm 71  
10709 Berlin, Germany  
Phone: +49 (0) 30 24603 349  
Fax: +49 (0) 30 24603 200  
E-mail: [ilts@ilts.org](mailto:ilts@ilts.org)



Association & Conference  
Management Group

## 2021 ILTS-SETH CONSENSUS CONFERENCE

Non-hepatic Cancer and Liver Transplantation: Shifting the Paradigm. Dropping the Cancer Stigma.



EACCME  
European Accreditation Council  
for Continuing Medical Education

### CONTINUING MEDICAL EDUCATION (CME) CREDITS

The **ILTS-SETH Consensus Conference on Non-hepatic Cancer and Liver Transplantation**, Berlin (streamed live), Germany, 28/01/2021-30/01/2021 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with **9 European CME credits** (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at [www.ama-assn.org/education/earn-credit-participation-international-activities](http://www.ama-assn.org/education/earn-credit-participation-international-activities).

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.